Dr. Martin Müller  -  CML - Chronic myeloid leukemia

Institute for Hematology and Oncology (IHO GmbH)

VIDEOS

Molecular monitoring in CML – getting  to a safe place
September 17, 2016, iCMLf


ARTICLES


Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
May 2018, The Lancet Oncology      

Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia
2004, PublMed